Unibest

Pharmaceutical intermediates

Lumateperone Tosylate Intermediates

4 pharmaceutical intermediates for Lumateperone Tosylate. Indication: Schizophrenia; Depressive Disorder, Major, Depression.

提交项目All intermediates

About Lumateperone Tosylate

Originator
Bristol Myers Squibb
Indication
Schizophrenia; Depressive Disorder, Major, Depression
Approved Date
04/22/2022
DS/DP
03/12/2029

Available intermediates

4 intermediates currently listed for Lumateperone Tosylate. Request specifications, documentation or a quotation for any item below.

Lumateperone Tosylate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(4aS,9bR)-Ethyl 6-bromo-5-(2-(methylamino)-2-oxoethyl)-3,4,4a,5-tetrahydro-1H-pyrido[4,3-b]indole-2(9bH)-carboxylate2098497-32-4//
(4aS,9bR)-6-bromo-1H,2H,3H,4H,4aH,5H,9bH-pyrido[4,3-b]indole,(2S)-2-hydroxy-2-phenylacetic acid1059630-13-5//
(6bR,10aS)-3-Methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline313368-85-3//
Ethyl2-oxo-2,3,9,10-tetrahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline-8(7H)-carboxylate313544-31-9//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Lumateperone Tosylate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →